Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population

This publication has 24 references indexed in Scilit:

• Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice
  Heart, 2001
• Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community
  Heart, 2000
• Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population
  Published by Oxford University Press (OUP) ,1999
• Biochemical detection of left-ventricular systolic dysfunction
  The Lancet, 1998
• Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
  The Lancet, 1997
• Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular Hypertrophy
  Hypertension, 1996
• Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
  The American Journal of Cardiology, 1996
• Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
  Circulation, 1993
• Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions
  New England Journal of Medicine, 1992
• Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
  New England Journal of Medicine, 1991